Who Owns Covetrus Company?

Covetrus Bundle

Get Full Bundle:

	SWOT	$15	$10
	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10

TOTAL:

ADD TO CART

Who Really Controls Covetrus?

Unraveling the ownership of Covetrus, a leading force in animal health technology and services, is key to understanding its strategic moves and market position. The Covetrus SWOT Analysis can also provide valuable insights. This exploration will illuminate the key players behind this global company, offering a deep dive into its financial performance and future trajectory.

The story of who owns Covetrus is a tale of strategic shifts, from its roots as a spin-off to its current status under private equity. Understanding the Covetrus ownership structure, including its major shareholders and the impact of the Covetrus acquisition, is crucial for anyone tracking the animal health industry. This analysis will also touch on the Covetrus company history and the implications for Covetrus stock, offering a comprehensive Covetrus company profile.

The story of Covetrus ownership begins with the merger of Henry Schein Animal Health and Vets First Choice in February 2019. While Covetrus company was officially established in 2019, the roots of Vets First Choice trace back to 2010, when Benjamin Shaw and his father, David Shaw, founded it.

David Shaw also has a notable background, having founded Idexx Laboratories Inc. in 1983. However, it's important to note that the name and initial business of Vets First Choice actually predate the Shaws' involvement, originating in 2007 with Professional Veterinary Products (PVP).

The Shaws later acquired Vets First Choice in 2010 after PVP faced bankruptcy. Details about the exact equity split among the founders at the company's inception as Covetrus are not publicly available.

Early Investors

Early backers for Vets First Choice included investors like Polaris Partners and HLM Venture Partners.

Funding Rounds

These investors contributed to a total funding of $292 million over seven rounds.

Initial Leadership

Benjamin Shaw became the first CEO of Covetrus upon its launch.

Board of Directors

David Shaw initially served as the chairman of the board.

Leadership Transition

David Shaw stepped down as chairman in September 2019 and announced his departure from the board in March 2020.

Shareholder

Prior to the 2022 privatization, Clayton, Dubilier & Rice (CD&R) was a significant shareholder, holding approximately 24% of Covetrus's outstanding common shares.

Key Takeaways on Covetrus

Understanding the Covetrus ownership structure is crucial for anyone interested in the Covetrus company. The early involvement of the Shaws and the subsequent backing from investors like Polaris Partners and HLM Venture Partners shaped the company's foundation. For more information on the company's strategic direction, you can read more about the Growth Strategy of Covetrus.

• The merger of Henry Schein Animal Health and Vets First Choice formed Covetrus in 2019.
• Benjamin Shaw and David Shaw played key roles in the founding of Vets First Choice.
• Early investors provided $292 million in funding.
• CD&R was a major shareholder before the 2022 privatization.

Covetrus SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The journey of Covetrus, a prominent player in the animal health industry, has seen significant shifts in its ownership structure. Initially, the Covetrus company emerged as a publicly traded entity in February 2019, following the merger of Henry Schein Animal Health and Vets First Choice. The company was listed on NASDAQ, marking its debut in the public market. However, this phase was relatively short-lived, as the company's ownership underwent a major transformation.

In May 2022, a pivotal agreement was reached for the Covetrus company to be acquired by the private equity firms Clayton, Dubilier & Rice (CD&R) and TPG Capital. This Covetrus acquisition, valued at approximately $4 billion, involved acquiring all outstanding shares of Covetrus stock not already held by CD&R affiliates. Before this agreement, CD&R and its affiliates already held around 24% of Covetrus's outstanding common shares. The acquisition was finalized on October 13, 2022, leading to Covetrus becoming a private company and being delisted from NASDAQ.

Currently, the major stakeholders of Covetrus are the private equity firms Clayton, Dubilier & Rice and TPG Capital. This transition from a publicly traded entity to private ownership has reshaped the company's strategic direction and governance. As a private entity, Covetrus is no longer subject to the same public reporting demands, and its strategic decisions are mainly influenced by its private equity owners. This shift may result in a greater focus on long-term growth initiatives and operational efficiencies, potentially reducing the immediate pressure from quarterly earnings reports. To understand the competitive landscape surrounding Covetrus, you can explore the Competitors Landscape of Covetrus.

Key Takeaways on Covetrus Ownership

The Covetrus ownership structure has evolved significantly since its inception, transitioning from a publicly traded company to private ownership. This shift was marked by the acquisition by Clayton, Dubilier & Rice (CD&R) and TPG Capital in 2022.

• Covetrus investors now primarily consist of private equity firms.
• The Covetrus company is no longer listed on NASDAQ.
• Strategic decisions are now primarily influenced by the private equity owners.
• The focus has shifted towards long-term growth and operational efficiencies.

Covetrus PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

Following the October 2022 acquisition and privatization, the board of directors and voting structure of the Covetrus company are largely influenced by its private equity owners, Clayton, Dubilier & Rice (CD&R) and TPG Capital. While specific details about the current board composition and affiliations aren't as publicly available as they were when the company was public, Benjamin Wolin remains the President and Chief Executive Officer and is a member of the Board of Directors. This structure reflects the typical governance of a private company, where control is consolidated within the ownership group.

Before privatization, CD&R's influence was evident. In April 2020, when CD&R invested $250 million in convertible preferred equity, their voting interest was capped at 19.99% of outstanding voting interests. They also had the right to appoint two directors to the board. This demonstrates the significant level of control exerted by CD&R, which likely evolved with the full acquisition. Understanding the Covetrus ownership structure is key to understanding the company's current direction, especially in the context of its recent transition from a public to a private entity.

As a private entity, the voting structure is streamlined, with the private equity firms holding the dominant voting power through their ownership stakes. This is a significant change from when Covetrus stock was publicly traded, where voting power was distributed among a broader shareholder base. Now, decision-making is more concentrated within the ownership group and the management team they oversee. This shift impacts how Covetrus investors might view the company, as the dynamics of governance and influence have fundamentally changed since the Covetrus acquisition.

Understanding Covetrus Ownership

The ownership structure of Covetrus company is now primarily controlled by private equity firms, CD&R and TPG Capital, following its privatization in October 2022.

• The board of directors is influenced by the private equity owners.
• Benjamin Wolin continues to lead as CEO and is on the board.
• Voting power is concentrated within the ownership group.
• Public governance controversies are less likely to occur.

Covetrus Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

The most significant shift in the Covetrus ownership landscape in recent years has been its transition from a publicly traded entity to a privately held one. In October 2022, Clayton, Dubilier & Rice (CD&R) and TPG Capital completed the acquisition of the Covetrus company for approximately $4 billion, which resulted in the delisting of Covetrus stock from NASDAQ. Prior to this, CD&R already held a considerable stake, owning roughly 24% of the company's outstanding shares. This change significantly altered the dynamics for Covetrus investors.

Leadership changes have also occurred within the Covetrus company. Benjamin Wolin continues to serve as President and CEO. In February 2024, Covetrus announced several promotions and appointments to elevated leadership roles. Amy Sanford was appointed as Global General Counsel and Chief Human Resources Officer, and Kelly Gottfried was promoted to Chief Commercial Officer for North America. As part of a restructuring initiative, an unspecified number of layoffs were implemented to support a 'simplified customer experience'.

The recent history of Covetrus reflects industry trends, particularly the increasing involvement of private equity. Private equity firms often acquire companies to implement operational improvements and strategic changes, away from the scrutiny of public markets, with the goal of increasing value. In 2024, Covetrus focused on enhancing veterinary practices and reported revenues of $4.9 billion. The company anticipates revenue growth in the low to mid-single-digit percentage range in 2024 and aims to expand S&P Global Ratings-adjusted EBITDA margins to about 4.1% in 2025. However, S&P Global Ratings revised Covetrus's outlook to negative in September 2024 due to operational headwinds and weakening market dynamics, anticipating continued cash flow deficits through 2027. To learn more about the company's strategic direction, you can explore the Growth Strategy of Covetrus.

Who Acquired Covetrus?

Clayton, Dubilier & Rice (CD&R) and TPG Capital acquired Covetrus in October 2022.

Is Covetrus a Public Company?

No, Covetrus is a privately held company since October 2022.

Who is the CEO of Covetrus?

Benjamin Wolin is the current President and CEO of Covetrus.

Covetrus Stock Symbol

Prior to going private, the stock symbol was CVET.

Covetrus Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔

Related Blogs